Skip nav

• The urine test, which identifies early markers of kidney damage, is not routinely carried out by GPs and nurses in annual reviews, mainly because many patients are reluctant to provide a urine sample(1)

CAMBRIDGE, UK: 24.02.20 – A new UK-wide survey, conducted by Napp Pharmaceuticals, suggests that over half (54%, n=403) of GPs and nurses who treat patients with type 2 diabetes (T2D) do not carry out a vital routine test annually, which is used to identify early markers of kidney damage.(1,2) The Urine Albumin-to-Creatinine Ratio (UACR) test is used to detect protein in the urine, signalling kidney damage which can lead to fatal complications.(2) According to survey respondents, the UACR test, which is recommended by UK guidelines for diabetes management (NICE and SIGN),(3,4) is not being administered annually to all patients as it should be because many patients are unwilling to provide a urine sample (38%, most frequent reason given by healthcare professionals...

Read full release